Increasing Patient Safety by Closing the Sterile Production Gap-Part 2. Implementation

Area of Science:

• Pharmaceutical Manufacturing
• Sterilization Technologies
• Microbial Control

Background:

• Terminal sterilization is the preferred method for sterile drug production due to enhanced patient safety.
• Current terminal sterilization processes are often unnecessarily harsh due to misconceptions about required conditions.
• This leads to limitations in sterilizing heat-sensitive drug formulations.

Purpose of the Study:

• To challenge the conventional, overly harsh time-temperature requirements for terminal sterilization.
• To propose a scientifically sound approach to optimize terminal sterilization processes.
• To expand the applicability of terminal sterilization to a wider range of drug products.

Main Methods:

• Re-evaluation of the primary goal of terminal sterilization from biological indicator destruction to bioburden elimination.
• Analysis of existing time-temperature sterilization parameters and their scientific basis.
• Development of a framework for identifying appropriate, less severe sterilization conditions.

Main Results:

• The study identifies that the focus on destroying highly resistant biological indicators is an artificial constraint.
• Recognizing bioburden destruction as the true goal allows for reduced sterilization parameters (lower temperature or shorter time).
• Optimized conditions can be implemented without increasing patient risk.

Conclusions:

• Terminal sterilization can be made more accessible for heat-sensitive products by adjusting process goals.
• Implementing reduced time-temperature conditions based on bioburden targets offers significant benefits.
• This approach enhances patient safety, producer efficiency, and regulatory flexibility.